Achieve Life Sciences Completes Enrollment Of 479 Participants In ORCA-OL Clinical Trial And Reports Outcome From First Data Safety Monitoring Committee Review With No Safety Concerns
Portfolio Pulse from Benzinga Newsdesk
Achieve Life Sciences has completed the enrollment of 479 participants in its ORCA-OL clinical trial and reported that the first Data Safety Monitoring Committee review found no safety concerns.
October 10, 2024 | 12:14 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Achieve Life Sciences has successfully enrolled 479 participants in its ORCA-OL clinical trial. The first safety review by the Data Safety Monitoring Committee reported no safety concerns, which is a positive indicator for the trial's progress.
The completion of participant enrollment and a positive safety review are significant milestones in a clinical trial. These developments suggest that the trial is progressing well, which could positively impact investor sentiment and the stock price of Achieve Life Sciences in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100